Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Now:
Last Hour:
Last 24 Hours:
Total:

Global Biosimilar (Insulin) Competitive Landscape and Market & Pipeline Analysis, 2016

Wednesday, November 16, 2016 1:25
% of readers think this story is Fact. Add your two cents.

(Before It's News)

Global Biosimilar (Insulin) Competitive Landscape and Market & Pipeline Analysis, 2016

DelveInsight’s, “Biosimilar (Insulin) – Competitive Landscape and Market & Pipeline Analysis, 2016” discusses the global insulin biosimilar industry. Report analyzes that Insulin and Insulin Biosimilars holds a future scope and potential in the market. It highlights the market trends, regulatory requirements for US and EU and key domestic players. 
Report provides an insight on Insulin Biosimilars that are under development for Type 1 and Type 2 Diabetes with an insight on the Epidemiology of the disease. It provides detailed information on the 11 Insulin Biosimilar that are in pipeline. 
It analyses Insulin Biosimilar industry and discusses the key market trends, major players, market assessment of 6 marketed insulin and the types of insulin with the length activity available in market. Report provides an update on the recent collaborations occurring in the insulin biosimilar market and the companies looking for partnership for the same. 

Try Sample Report @ https://www.wiseguyreports.com/sample-request/476534-biosimilar-insulin-competitive-landscape-and-market-pipeline-analysis-2016

Scope: 
§ Coverage of global insulin biosimilar under development across the globe 
§ Sales forecast for marketed insulin from 2015 to 2017 
§ Detailed information on product description and related stage of development, the mode of therapy, mechanism of action, development partner and technology information. 
§ The report discusses the biosimilar regulatory landscape of various markets including developed markets of the US and EU 
§ Report analyses the types of insulin under development with respect to their market share and length of activity

Reason to Buy 
§ The insulin biosimilar report covers complete Pipeline intelligence and understanding over therapeutics development for insulin market. 
§ Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
§ Identify and understand important and diverse types of insulin under development 
§ Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline 
§ Devise corrective measures for pipeline projects by understanding the insulin biosimilar pipeline in-depth 
§ Identifying the upcoming leaders in the insulin biosimilar market in the coming year

Access Complete Report @ https://www.wiseguyreports.com/reports/476534-biosimilar-insulin-competitive-landscape-and-market-pipeline-analysis-2016

Table of contents: 
Executive Summary 
Biosimilar 
History of Insulin and Insulin Biosimilar Development 
Regulatory Pathways in US and EU 
Illustration of the Originator and Biosimilar Development 
Major Indication 
Epidemology 
Complications Associated with Diabetes 
Diagnosis of Diabetes 
Analysis 
Clinical Trials 
Technology 
Market Assessment 
Market Trends 
Drivers 
Barriers 
Historical Sales Data for the Marketed Drugs 
Forecasted Sales Data for the Marketed Drugs 
Major Competitors 
Types of insulin and length of activity 
Pipeline Therapeutics 
Therapeutics under Development by Companies 
Therapeutic Assessment 
Assessment by Monotherapy Products 
Assessment by Combination Products 
Assessment by Route of Administration 
Assessment by Stage and Route of Administration 
Assessment by Molecule Type 
Assessment by Stage and Molecule Type 
Dormant Products 
Product Development Activities 
Companies involved in Therapeutics Development 
Appendix 
Methodology 
Consulting Services 
About DelveInsight 
Contact Us 
Disclaimer

List of Table: 
Table 1:Marketed Insulin Details, 2016 
Table 8: Historical Global Sales of Marketed Insulin Analogs 2011-2014 (in million USD), 2016 
Table 9: Forecasted Global Sales of Marketed Insulin Analogs 2015-2017 (in million USD), 2016 
Table 10:Number of Products Under Development for Insulin Biosimilars,2016 
Table 11: Number of Products under Development by Companies,2016 
Table 12: Late Stage Products (Phase III and Filed), 2016 
Table 13: Early Stage Products (Phase I and IND),2016 
Table 14: Pre-Clinical and Discovery Products, 2016 
Table 15: Assessment by Monotherapy Products, 2016 
Table 16: Assessment by Combination Products, 2016 
Table 17: Assessment by Route Of Administration, 2016 
Table 18:Assessment by Stage and Route Of Administration, 2016 
Table 19: Assessment by Molecule Type, 2016 
Table 20: Assessment by Stage and Molecule Type, 2016 
Table 21: Dormant Products, 2016

List of figures: 
Figure 1: Number of products with ongoing and completed clinical trials, 2016 
Figure 2: Number of products with ongoing and completed clinical trials, 2016 
Figure 3: Number of products in clinical trials with companies, 2016 
Figure 4: Number of technology associated with the companies, 2016 
Figure 5: Number of Product with Insulin Biosimilar Technology, 2016 
Figure 6: Historical Global Sales of Marketed Insulin Analogs 2011-2014 (in million USD), 2016 
Figure 7: Forecasted Global Sales of Marketed Insulin Analogs 2015-2017 (in million USD), 2016 
Figure 8: Types of Insulin Biosimilar Under Development, 2016 
Figure 9: Number of different type of Insulin Biosimilar and Company, 2016 
Figure 10: Number of Products under Development for Insulin Biosimilars, 2016 
Figure 11: Late Stage Products (Phase III), 2016 
Figure 12: Mid Stage Products (Phase II),2016 
Figure 13: Early Stage Products (Phase I and IND), 2016 
Figure 14:Pre-Clinical and Discovery Products, 2016 
Figure 15: Assessment by Monotherapy Products, 2016 
Figure 16: Assessment by Combination Products, 2016 
Figure 17: Assessment by Route of Administration, 2016 
Figure 18: Assessment by Stage and Route of Administration, 2016 
Figure 19: Assessment by Molecule Type, 2016 
Figure 20: Assessment by Stage and Molecule Type, 2016 
Figure 21: Dormant Products, 2016

Buy Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=476534

For more information or any query mail at sales@wiseguyreports.com

Contact Us:
Norah Trent
+1 646 845 9349 / +44 208 133 9349
Follow on LinkedIn: 
https://www.linkedin.com/company/wise-guy-research-consultants-pvt-ltd-?trk=biz-companies-cym

Report abuse

Comments

Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories

Register

Newsletter

Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.